Mapping the effectiveness and risks of GLP-1 receptor agonists
- Design
- Retrospective cohort · 215970 participants · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationVeterans with diabetes, mostly older men; useful hypothesis atlas for both benefits and harms, not causal evidence.
- Could weight loss explain it?
- UnknownDiscovery-approach cohort; no mediation analysis.
- Study tier
- Study tier 3Large systematic observational screen; hypothesis-generating across all outcomes.
- Assessment
- Version 2 · curated · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
A systematic scan of 175 outcomes in 215,970 US veterans with diabetes starting GLP-1 drugs found lower rates of many conditions (including substance use and dementia) and higher rates of gastrointestinal problems, low blood pressure, fainting, joint disorders, kidney stones and pancreatitis. Observational; useful for generating hypotheses in both directions.
01Findings
What the study reported
- Drugs
- Class unspecified
- Comparator
- sulfonylureas, DPP-4i, SGLT2i, and usual care
- Primary outcome
- Discovery atlas of 175 outcomes (VA cohort of people with diabetes)
- Effect
- Reduced: substance use, psychotic disorders, seizures, neurocognitive disorders, cardiometabolic, infections, respiratory. Increased: GI disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis, drug-induced pancreatitis (vs usual care)
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Sex distribution
- predominantly male (VA)
- Obesity status
- obesity/overweight present (all or most)
- Diabetes status
- diabetes (all; US veterans)
- Baseline condition
- Alzheimer's disease / MCI
- Sample size
- 215970
Study quality details
- Study design
- Retrospective cohort
- Sample size
- 215970
- Randomization
- no
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- not stated
- Outcome type
- hard
- Replication
- single cohort
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- not extracted
- Risk of bias
- confounding by indication and healthy-adherer bias; multiple comparisons
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- US Department of Veterans Affairs (full text)
- Industry funded
- No
- Manufacturer
- Pfizer
- Sponsor role
- not reported in abstract
- Author conflicts
- Authors are uncompensated consultants for Pfizer.
- Independent replication
- partial for individual outcomes
Funding is shown on every study and never used to score it.
03Claims
Claims this study bears on
- GLP-1 receptor agonist therapy provides a net clinical benefit to healthy normal-weight adults aged 55-75.Mixed
Broad benefit/harm atlas in veterans with diabetes; includes increased arthritic disorders, hypotension, pancreatitis, nephrolithiasis.
- GLP-1 receptor agonist treatment reduces the risk of developing dementia.Supports
VA atlas: reduced neurocognitive disorders vs usual care; observational.
- GLP-1 receptor agonists reduce alcohol and other substance use.Supports
VA atlas: reduced substance use disorders vs usual care; observational.
- GLP-1 receptor agonists cause serious gastrointestinal and biliary adverse events.Supports
VA atlas: GI disorders, drug-induced pancreatitis increased.
04Source
The source, as retrieved
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. However, their effectiveness and risks have not yet been systematically evaluated in a comprehensive set of possible health outcomes. Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA (n = 215,970) and compared them to those who initiated sulfonylureas (n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors (n = 117,989) or sodium-glucose cotransporter-2 (SGLT2) inhibitors (n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors (n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care). We used a discovery approach to systematically map an atlas of the associations of GLP-1RA use versus each comparator with 175 health outcomes. Compared to usual care, GLP-1RA use was associated with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer's disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions. There was an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis associated with GLP-1RA use compared to usual care. The results provide insights into the benefits and risks of GLP-1RAs and may be useful for informing clinical care and guiding research agendas.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 13, 2026 | 39833406 first ingestion |